Unlike general health products stocked in every health store, CJC-1295 reaches researchers through a specialist research supply market that Hamm residents access almost entirely online. This matters because CJC-1295 quality varies dramatically across the market — from analytically confirmed high-purity product to mislabeled or underdosed compounds — and the vendor controls every quality variable. What genuinely separates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for contamination assurance. Use this guide to assess sourcing options methodically — the framework here work regardless of your location.
CJC-1295 Mechanisms Explained
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Hamm researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
Vetting CJC-1295 vendors requires starting from the COA: request the batch-specific certificate before purchasing, not after. When reviewing a CJC-1295 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are at acceptable levels for the intended application. For Hamm researchers evaluating unfamiliar vendors: a test quantity before committing to research volumes before scaling up your order is the accepted approach among experienced researchers. Price is an unreliable primary filter for CJC-1295 quality — research-grade synthesis and testing has real costs that do not compress without quality compromise, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Hamm
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and restricted human research data. Proper handling of CJC-1295 requires sterile reconstitution technique — alcohol-swabbed septum, fresh needles, clean working environment — and consistent cold chain handling. Endotoxin testing in the CJC-1295 COA is absolutely required — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at very low concentrations, and no pricing advantage justifies skipping this verification. Researchers combining CJC-1295 with other compounds should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
